SCHEMBL25258233

SCHEMBL25258233

Cc1ccc(S(=O)(=O)Oc2cc(OS(=O)(=O)c3ccc(C)cc3)c(C(=O)O)c(OCc3ccc(F)cc3)c2C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 9/20 0.47
NFE2L2 Q16236 9/20 0.47
ANO1 Q5XXA6 1/20 0.43
TAS2R14 Q9NYV8 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
FFAR4 Q5NUL3 1/20 0.40
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN6 P29350 1/20 0.39
PPARG P37231 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
NR4A2 P43354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25220696 0.90 KEAP1 (0.44) KEAP1NFE2L2LMNAPTPN1ALDH1A1
SCHEMBL30431568 0.85 THRA (0.43) KEAP1NFE2L2TAS2R14FFAR4ALDH1A1
SCHEMBL25251372 0.85 THRA (0.43) KEAP1NFE2L2TAS2R14FFAR4ALDH1A1
SCHEMBL25215463 0.84 KEAP1 (0.50) KEAP1NFE2L2ANO1TAS2R14LMNA
SCHEMBL25273055 0.83 GAA (0.48) LMNAPPARGALDH1A1GAAHPGD
SCHEMBL25214730 0.83 KEAP1 (0.42) KEAP1NFE2L2LMNAPTPN2PTPN1
SCHEMBL31282678 0.82 KMT2A (0.40) LMNAHTTPTPN2PTPN1PTPN6
SCHEMBL31062494 0.80 KEAP1 (0.46) KEAP1NFE2L2TAS2R14FFAR4EGFR
SCHEMBL30368388 0.80 ALDH1A1 (0.49) LMNAHTTALDH1A1GAAHPGD
SCHEMBL25669111 0.80 ALDH1A1 (0.49) LMNAHTTALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552758-B2 Inhibitors of MLH1 and/or PMS2 for cancer treatment Neophore Limited (GB) 2026-02-17 US disclosed
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT Neophore Limited (GB) 2023-06-15 US disclosed
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT Neophore Limited (GB) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552758-B2 Inhibitors of MLH1 and/or PMS2 for cancer treatment MSH2, PMS2, MSH6 KEAP1 278/4885NFE2L2 587/4885ANO1 2637/4885
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT MSH2, PMS2, MSH6 KEAP1 143/4885NFE2L2 155/4885ANO1 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.